Precision Health Clinical Trials

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Conditions:   Cancer;   Tumors;   Neoplasms;   Neoplasia
Interventions:   Drug: Alectinib;   Drug: Atezolizumab;   Drug: Avelumab;   Drug: Axitinib;   Drug: Erlotinib;   Drug: Vemurafenib plus Cobimetinib (combination);   Drug: Trastuzumab plus Pertuzumab (combination);   Drug: Trastuzumab emtansine;   Drug: Vismodegib;   Drug: Niraparib
Sponsors:   Ulrik Lassen;   Roche Pharma AG;   Pfizer;   GlaxoSmithKline
Recruiting

Evolution of Multiple Primary Lung Cancer (Evolution)

Conditions:   Multiple Primary Lung Cancers;   Lung Cancer;   Non Small Cell Lung Cancer
Intervention:  
Sponsors:   Peking University People's Hospital;   Guangzhou Burning Rock Medical Examination Institute Co., Ltd.
Not yet recruiting

A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa

Conditions:   Diarrhea;   Diarrhea Infectious
Intervention:   Other: no intervention
Sponsors:   Centre for Infectious Disease Research in Zambia;   European Vaccine Initiative;   Groupe de Recherche Action en Sante;   European and Developing Countries Clinical Trials Partnership (EDCTP)
Recruiting

Genes and Environment in Multiple Sclerosis

Condition:   Multiple Sclerosis
Intervention:  
Sponsors:   Columbia University;   University of Pittsburgh;   Brigham and Women's Hospital
Recruiting

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

Conditions:   Prostate Cancer;   Advanced Renal Cell Carcinoma;   Advanced Urothelial Carcinoma;   Genitourinary Cancer
Interventions:   Other: Systemic therapy;   Device: StrataNGS
Sponsors:   University of California, San Francisco;   Prostate Cancer Foundation;   Strata Oncology
Recruiting

GEN2 Directed Cancer Immunotherapy Trial

Conditions:   Hepatocellular Carcinoma;   Metastatic Cancer
Intervention:   Drug: GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
Sponsor:   GenVivo, Inc.
Recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Conditions:   Malignant Solid Neoplasm;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Ectomesenchymoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Kidney Wilms Tumor;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Melanoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdoid Tumor of the Kidney;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent WHO Grade 2 Glioma;   Refractory Adrenal Gland Pheochromocytoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Melanoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdoid Tumor of the Kidney;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Refractory Thyroid Gland Carcinoma;   Refractory WHO Grade 2 Glioma
Intervention:   Drug: Tipifarnib
Sponsor:   National Cancer Institute (NCI)
Recruiting

PDAC Peripheral and Portal Vein Sampling

Condition:   Pancreatic Adenocarcinoma
Intervention:   Diagnostic Test: Portal vein sampling
Sponsors:   The Christie NHS Foundation Trust;   Manchester University NHS Foundation Trust
Recruiting

Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Palbociclib
Sponsors:   Chinese Academy of Medical Sciences;   OrigiMed
Recruiting

Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Conditions:   Breast Cancer;   Lung Cancer;   Gastrointestinal Cancer;   Genitourinary Cancer;   Gynecologic Cancer;   Sarcoma;   Unknown Primary Tumors;   Head and Neck Cancer;   Skin Cancer
Intervention:   Drug: Atezolizumab
Sponsors:   British Columbia Cancer Agency;   Hoffmann-La Roche
Recruiting

Pages